Global Autoimmune Hemolytic Anemia Therapeutics Market Research Report 2023

Autoimmune Hemolytic Anemia (AHA) is also called immune hemolytic anemia. It is an immune and rare red blood cell disorder. Autoimmune hemolytic anemia occurs when the immune system makes antibodies that attack red blood cells in the body. This decreases the number of red blood cells, resulting to hemolytic anemia.

The global Autoimmune Hemolytic Anemia Therapeutics market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

North American market for Autoimmune Hemolytic Anemia Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

Asia-Pacific market for Autoimmune Hemolytic Anemia Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The global market for Autoimmune Hemolytic Anemia Therapeutics in Hospital Pharmacies is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The key global companies of Autoimmune Hemolytic Anemia Therapeutics include Amneal Pharmaceuticals Inc, Baxter International Inc, F. Hoffmann-La Roche Ltd, Incyte Corp, Kezar Life Sciences Inc, Pfizer Inc, Rigel Pharmaceuticals Inc, Sanofi and Teva Pharmaceutical Industries Ltd, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Autoimmune Hemolytic Anemia Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Autoimmune Hemolytic Anemia Therapeutics.

The Autoimmune Hemolytic Anemia Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Autoimmune Hemolytic Anemia Therapeutics market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Autoimmune Hemolytic Anemia Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

1.1 Study Scope

1.2 Market Analysis By Drug Class

1.2.1 Global Autoimmune Hemolytic Anemia Therapeutics Market Size Growth Rate By Drug Class: 2018 VS 2022 VS 2029

1.2.2 Corticosteroids

1.2.3 Monoclonal Antibodies

1.2.4 Others

1.3 Market by Application

1.3.1 Global Autoimmune Hemolytic Anemia Therapeutics Market Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Hospital Pharmacies

1.3.3 Retail Pharmacies

1.3.4 Online Pharmacies

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2.1 Global Autoimmune Hemolytic Anemia Therapeutics Market Perspective (2018-2029)

2.2 Autoimmune Hemolytic Anemia Therapeutics Growth Trends by Region

2.2.1 Global Autoimmune Hemolytic Anemia Therapeutics Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Autoimmune Hemolytic Anemia Therapeutics Historic Market Size by Region (2018-2023)

2.2.3 Autoimmune Hemolytic Anemia Therapeutics Forecasted Market Size by Region (2024-2029)

2.3 Autoimmune Hemolytic Anemia Therapeutics Market Dynamics

2.3.1 Autoimmune Hemolytic Anemia Therapeutics Industry Trends

2.3.2 Autoimmune Hemolytic Anemia Therapeutics Market Drivers

2.3.3 Autoimmune Hemolytic Anemia Therapeutics Market Challenges

2.3.4 Autoimmune Hemolytic Anemia Therapeutics Market Restraints

3.1 Global Top Autoimmune Hemolytic Anemia Therapeutics Players by Revenue

3.1.1 Global Top Autoimmune Hemolytic Anemia Therapeutics Players by Revenue (2018-2023)

3.1.2 Global Autoimmune Hemolytic Anemia Therapeutics Revenue Market Share by Players (2018-2023)

3.2 Global Autoimmune Hemolytic Anemia Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Autoimmune Hemolytic Anemia Therapeutics Revenue

3.4 Global Autoimmune Hemolytic Anemia Therapeutics Market Concentration Ratio

3.4.1 Global Autoimmune Hemolytic Anemia Therapeutics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Autoimmune Hemolytic Anemia Therapeutics Revenue in 2022

3.5 Autoimmune Hemolytic Anemia Therapeutics Key Players Head office and Area Served

3.6 Key Players Autoimmune Hemolytic Anemia Therapeutics Product Solution and Service

3.7 Date of Enter into Autoimmune Hemolytic Anemia Therapeutics Market

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global Autoimmune Hemolytic Anemia Therapeutics Historic Market Size by Type (2018-2023)

4.2 Global Autoimmune Hemolytic Anemia Therapeutics Forecasted Market Size by Type (2024-2029)

5.1 Global Autoimmune Hemolytic Anemia Therapeutics Historic Market Size by Application (2018-2023)

5.2 Global Autoimmune Hemolytic Anemia Therapeutics Forecasted Market Size by Application (2024-2029)

6.1 North America Autoimmune Hemolytic Anemia Therapeutics Market Size (2018-2029)

6.2 North America Autoimmune Hemolytic Anemia Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Autoimmune Hemolytic Anemia Therapeutics Market Size by Country (2018-2023)

6.4 North America Autoimmune Hemolytic Anemia Therapeutics Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7.1 Europe Autoimmune Hemolytic Anemia Therapeutics Market Size (2018-2029)

7.2 Europe Autoimmune Hemolytic Anemia Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Autoimmune Hemolytic Anemia Therapeutics Market Size by Country (2018-2023)

7.4 Europe Autoimmune Hemolytic Anemia Therapeutics Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8.1 Asia-Pacific Autoimmune Hemolytic Anemia Therapeutics Market Size (2018-2029)

8.2 Asia-Pacific Autoimmune Hemolytic Anemia Therapeutics Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Autoimmune Hemolytic Anemia Therapeutics Market Size by Region (2018-2023)

8.4 Asia-Pacific Autoimmune Hemolytic Anemia Therapeutics Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9.1 Latin America Autoimmune Hemolytic Anemia Therapeutics Market Size (2018-2029)

9.2 Latin America Autoimmune Hemolytic Anemia Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Autoimmune Hemolytic Anemia Therapeutics Market Size by Country (2018-2023)

9.4 Latin America Autoimmune Hemolytic Anemia Therapeutics Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10.1 Middle East & Africa Autoimmune Hemolytic Anemia Therapeutics Market Size (2018-2029)

10.2 Middle East & Africa Autoimmune Hemolytic Anemia Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Autoimmune Hemolytic Anemia Therapeutics Market Size by Country (2018-2023)

10.4 Middle East & Africa Autoimmune Hemolytic Anemia Therapeutics Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11.1 Amneal Pharmaceuticals Inc

11.1.1 Amneal Pharmaceuticals Inc Company Detail

11.1.2 Amneal Pharmaceuticals Inc Business Overview

11.1.3 Amneal Pharmaceuticals Inc Autoimmune Hemolytic Anemia Therapeutics Introduction

11.1.4 Amneal Pharmaceuticals Inc Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023)

11.1.5 Amneal Pharmaceuticals Inc Recent Development

11.2 Baxter International Inc

11.2.1 Baxter International Inc Company Detail

11.2.2 Baxter International Inc Business Overview

11.2.3 Baxter International Inc Autoimmune Hemolytic Anemia Therapeutics Introduction

11.2.4 Baxter International Inc Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023)

11.2.5 Baxter International Inc Recent Development

11.3 F. Hoffmann-La Roche Ltd

11.3.1 F. Hoffmann-La Roche Ltd Company Detail

11.3.2 F. Hoffmann-La Roche Ltd Business Overview

11.3.3 F. Hoffmann-La Roche Ltd Autoimmune Hemolytic Anemia Therapeutics Introduction

11.3.4 F. Hoffmann-La Roche Ltd Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023)

11.3.5 F. Hoffmann-La Roche Ltd Recent Development

11.4 Incyte Corp

11.4.1 Incyte Corp Company Detail

11.4.2 Incyte Corp Business Overview

11.4.3 Incyte Corp Autoimmune Hemolytic Anemia Therapeutics Introduction

11.4.4 Incyte Corp Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023)

11.4.5 Incyte Corp Recent Development

11.5 Kezar Life Sciences Inc

11.5.1 Kezar Life Sciences Inc Company Detail

11.5.2 Kezar Life Sciences Inc Business Overview

11.5.3 Kezar Life Sciences Inc Autoimmune Hemolytic Anemia Therapeutics Introduction

11.5.4 Kezar Life Sciences Inc Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023)

11.5.5 Kezar Life Sciences Inc Recent Development

11.6 Pfizer Inc

11.6.1 Pfizer Inc Company Detail

11.6.2 Pfizer Inc Business Overview

11.6.3 Pfizer Inc Autoimmune Hemolytic Anemia Therapeutics Introduction

11.6.4 Pfizer Inc Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023)

11.6.5 Pfizer Inc Recent Development

11.7 Rigel Pharmaceuticals Inc

11.7.1 Rigel Pharmaceuticals Inc Company Detail

11.7.2 Rigel Pharmaceuticals Inc Business Overview

11.7.3 Rigel Pharmaceuticals Inc Autoimmune Hemolytic Anemia Therapeutics Introduction

11.7.4 Rigel Pharmaceuticals Inc Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023)

11.7.5 Rigel Pharmaceuticals Inc Recent Development

11.8 Sanofi

11.8.1 Sanofi Company Detail

11.8.2 Sanofi Business Overview

11.8.3 Sanofi Autoimmune Hemolytic Anemia Therapeutics Introduction

11.8.4 Sanofi Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023)

11.8.5 Sanofi Recent Development

11.9 Teva Pharmaceutical Industries Ltd

11.9.1 Teva Pharmaceutical Industries Ltd Company Detail

11.9.2 Teva Pharmaceutical Industries Ltd Business Overview

11.9.3 Teva Pharmaceutical Industries Ltd Autoimmune Hemolytic Anemia Therapeutics Introduction

11.9.4 Teva Pharmaceutical Industries Ltd Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023)

11.9.5 Teva Pharmaceutical Industries Ltd Recent Development

11.10 Horizo​​n

11.10.1 Horizo​​n Company Detail

11.10.2 Horizo​​n Business Overview

11.10.3 Horizo​​n Autoimmune Hemolytic Anemia Therapeutics Introduction

11.10.4 Horizo​​n Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023)

11.10.5 Horizo​​n Recent Development

11.11 Genentech

11.11.1 Genentech Company Detail

11.11.2 Genentech Business Overview

11.11.3 Genentech Autoimmune Hemolytic Anemia Therapeutics Introduction

11.11.4 Genentech Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023)

11.11.5 Genentech Recent Development

11.12 Zydus Cadila

11.12.1 Zydus Cadila Company Detail

11.12.2 Zydus Cadila Business Overview

11.12.3 Zydus Cadila Autoimmune Hemolytic Anemia Therapeutics Introduction

11.12.4 Zydus Cadila Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023)

11.12.5 Zydus Cadila Recent Development

11.13 Concord Biotech

11.13.1 Concord Biotech Company Detail

11.13.2 Concord Biotech Business Overview

11.13.3 Concord Biotech Autoimmune Hemolytic Anemia Therapeutics Introduction

11.13.4 Concord Biotech Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023)

11.13.5 Concord Biotech Recent Development

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

    Table 1. Global Autoimmune Hemolytic Anemia Therapeutics Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029

    Table 2. Key Players of Corticosteroids

    Table 3. Key Players of Monoclonal Antibodies

    Table 4. Key Players of Others

    Table 5. Global Autoimmune Hemolytic Anemia Therapeutics Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029

    Table 6. Global Autoimmune Hemolytic Anemia Therapeutics Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 7. Global Autoimmune Hemolytic Anemia Therapeutics Market Size by Region (2018-2023) & (US$ Million)

    Table 8. Global Autoimmune Hemolytic Anemia Therapeutics Market Share by Region (2018-2023)

    Table 9. Global Autoimmune Hemolytic Anemia Therapeutics Forecasted Market Size by Region (2024-2029) & (US$ Million)

    Table 10. Global Autoimmune Hemolytic Anemia Therapeutics Market Share by Region (2024-2029)

    Table 11. Autoimmune Hemolytic Anemia Therapeutics Market Trends

    Table 12. Autoimmune Hemolytic Anemia Therapeutics Market Drivers

    Table 13. Autoimmune Hemolytic Anemia Therapeutics Market Challenges

    Table 14. Autoimmune Hemolytic Anemia Therapeutics Market Restraints

    Table 15. Global Autoimmune Hemolytic Anemia Therapeutics Revenue by Players (2018-2023) & (US$ Million)

    Table 16. Global Autoimmune Hemolytic Anemia Therapeutics Market Share by Players (2018-2023)

    Table 17. Global Top Autoimmune Hemolytic Anemia Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Autoimmune Hemolytic Anemia Therapeutics as of 2022)

    Table 18. Ranking of Global Top Autoimmune Hemolytic Anemia Therapeutics Companies by Revenue (US$ Million) in 2022

    Table 19. Global 5 Largest Players Market Share by Autoimmune Hemolytic Anemia Therapeutics Revenue (CR5 and HHI) & (2018-2023)

    Table 20. Key Players Headquarters and Area Served

    Table 21. Key Players Autoimmune Hemolytic Anemia Therapeutics Product Solution and Service

    Table 22. Date of Enter into Autoimmune Hemolytic Anemia Therapeutics Market

    Table 23. Mergers & Acquisitions, Expansion Plans

    Table 24. Global Autoimmune Hemolytic Anemia Therapeutics Market Size by Type (2018-2023) & (US$ Million)

    Table 25. Global Autoimmune Hemolytic Anemia Therapeutics Revenue Market Share by Type (2018-2023)

    Table 26. Global Autoimmune Hemolytic Anemia Therapeutics Forecasted Market Size by Type (2024-2029) & (US$ Million)

    Table 27. Global Autoimmune Hemolytic Anemia Therapeutics Revenue Market Share by Type (2024-2029)

    Table 28. Global Autoimmune Hemolytic Anemia Therapeutics Market Size by Application (2018-2023) & (US$ Million)

    Table 29. Global Autoimmune Hemolytic Anemia Therapeutics Revenue Market Share by Application (2018-2023)

    Table 30. Global Autoimmune Hemolytic Anemia Therapeutics Forecasted Market Size by Application (2024-2029) & (US$ Million)

    Table 31. Global Autoimmune Hemolytic Anemia Therapeutics Revenue Market Share by Application (2024-2029)

    Table 32. North America Autoimmune Hemolytic Anemia Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 33. North America Autoimmune Hemolytic Anemia Therapeutics Market Size by Country (2018-2023) & (US$ Million)

    Table 34. North America Autoimmune Hemolytic Anemia Therapeutics Market Size by Country (2024-2029) & (US$ Million)

    Table 35. Europe Autoimmune Hemolytic Anemia Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 36. Europe Autoimmune Hemolytic Anemia Therapeutics Market Size by Country (2018-2023) & (US$ Million)

    Table 37. Europe Autoimmune Hemolytic Anemia Therapeutics Market Size by Country (2024-2029) & (US$ Million)

    Table 38. Asia-Pacific Autoimmune Hemolytic Anemia Therapeutics Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 39. Asia-Pacific Autoimmune Hemolytic Anemia Therapeutics Market Size by Region (2018-2023) & (US$ Million)

    Table 40. Asia-Pacific Autoimmune Hemolytic Anemia Therapeutics Market Size by Region (2024-2029) & (US$ Million)

    Table 41. Latin America Autoimmune Hemolytic Anemia Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 42. Latin America Autoimmune Hemolytic Anemia Therapeutics Market Size by Country (2018-2023) & (US$ Million)

    Table 43. Latin America Autoimmune Hemolytic Anemia Therapeutics Market Size by Country (2024-2029) & (US$ Million)

    Table 44. Middle East & Africa Autoimmune Hemolytic Anemia Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 45. Middle East & Africa Autoimmune Hemolytic Anemia Therapeutics Market Size by Country (2018-2023) & (US$ Million)

    Table 46. Middle East & Africa Autoimmune Hemolytic Anemia Therapeutics Market Size by Country (2024-2029) & (US$ Million)

    Table 47. Amneal Pharmaceuticals Inc Company Detail

    Table 48. Amneal Pharmaceuticals Inc Business Overview

    Table 49. Amneal Pharmaceuticals Inc Autoimmune Hemolytic Anemia Therapeutics Product

    Table 50. Amneal Pharmaceuticals Inc Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023) & (US$ Million)

    Table 51. Amneal Pharmaceuticals Inc Recent Development

    Table 52. Baxter International Inc Company Detail

    Table 53. Baxter International Inc Business Overview

    Table 54. Baxter International Inc Autoimmune Hemolytic Anemia Therapeutics Product

    Table 55. Baxter International Inc Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023) & (US$ Million)

    Table 56. Baxter International Inc Recent Development

    Table 57. F. Hoffmann-La Roche Ltd Company Detail

    Table 58. F. Hoffmann-La Roche Ltd Business Overview

    Table 59. F. Hoffmann-La Roche Ltd Autoimmune Hemolytic Anemia Therapeutics Product

    Table 60. F. Hoffmann-La Roche Ltd Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023) & (US$ Million)

    Table 61. F. Hoffmann-La Roche Ltd Recent Development

    Table 62. Incyte Corp Company Detail

    Table 63. Incyte Corp Business Overview

    Table 64. Incyte Corp Autoimmune Hemolytic Anemia Therapeutics Product

    Table 65. Incyte Corp Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023) & (US$ Million)

    Table 66. Incyte Corp Recent Development

    Table 67. Kezar Life Sciences Inc Company Detail

    Table 68. Kezar Life Sciences Inc Business Overview

    Table 69. Kezar Life Sciences Inc Autoimmune Hemolytic Anemia Therapeutics Product

    Table 70. Kezar Life Sciences Inc Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023) & (US$ Million)

    Table 71. Kezar Life Sciences Inc Recent Development

    Table 72. Pfizer Inc Company Detail

    Table 73. Pfizer Inc Business Overview

    Table 74. Pfizer Inc Autoimmune Hemolytic Anemia Therapeutics Product

    Table 75. Pfizer Inc Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023) & (US$ Million)

    Table 76. Pfizer Inc Recent Development

    Table 77. Rigel Pharmaceuticals Inc Company Detail

    Table 78. Rigel Pharmaceuticals Inc Business Overview

    Table 79. Rigel Pharmaceuticals Inc Autoimmune Hemolytic Anemia Therapeutics Product

    Table 80. Rigel Pharmaceuticals Inc Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023) & (US$ Million)

    Table 81. Rigel Pharmaceuticals Inc Recent Development

    Table 82. Sanofi Company Detail

    Table 83. Sanofi Business Overview

    Table 84. Sanofi Autoimmune Hemolytic Anemia Therapeutics Product

    Table 85. Sanofi Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023) & (US$ Million)

    Table 86. Sanofi Recent Development

    Table 87. Teva Pharmaceutical Industries Ltd Company Detail

    Table 88. Teva Pharmaceutical Industries Ltd Business Overview

    Table 89. Teva Pharmaceutical Industries Ltd Autoimmune Hemolytic Anemia Therapeutics Product

    Table 90. Teva Pharmaceutical Industries Ltd Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023) & (US$ Million)

    Table 91. Teva Pharmaceutical Industries Ltd Recent Development

    Table 92. Horizo​​n Company Detail

    Table 93. Horizo​​n Business Overview

    Table 94. Horizo​​n Autoimmune Hemolytic Anemia Therapeutics Product

    Table 95. Horizo​​n Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023) & (US$ Million)

    Table 96. Horizo​​n Recent Development

    Table 97. Genentech Company Detail

    Table 98. Genentech Business Overview

    Table 99. Genentech Autoimmune Hemolytic Anemia Therapeutics Product

    Table 100. Genentech Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023) & (US$ Million)

    Table 101. Genentech Recent Development

    Table 102. Zydus Cadila Company Detail

    Table 103. Zydus Cadila Business Overview

    Table 104. Zydus Cadila Autoimmune Hemolytic Anemia Therapeutics Product

    Table 105. Zydus Cadila Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023) & (US$ Million)

    Table 106. Zydus Cadila Recent Development

    Table 107. Concord Biotech Company Detail

    Table 108. Concord Biotech Business Overview

    Table 109. Concord Biotech Autoimmune Hemolytic Anemia Therapeutics Product

    Table 110. Concord Biotech Revenue in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023) & (US$ Million)

    Table 111. Concord Biotech Recent Development

    Table 112. Research Programs/Design for This Report

    Table 113. Key Data Information from Secondary Sources

    Table 114. Key Data Information from Primary Sources

List of Figures

    Figure 1. Global Autoimmune Hemolytic Anemia Therapeutics Market Size Comparison by Type (2023-2029) & (US$ Million)

    Figure 2. Global Autoimmune Hemolytic Anemia Therapeutics Market Share by Type: 2022 VS 2029

    Figure 3. Corticosteroids Features

    Figure 4. Monoclonal Antibodies Features

    Figure 5. Others Features

    Figure 6. Global Autoimmune Hemolytic Anemia Therapeutics Market Size Comparison by Application (2023-2029) & (US$ Million)

    Figure 7. Global Autoimmune Hemolytic Anemia Therapeutics Market Share by Application: 2022 VS 2029

    Figure 8. Hospital Pharmacies Case Studies

    Figure 9. Retail Pharmacies Case Studies

    Figure 10. Online Pharmacies Case Studies

    Figure 11. Autoimmune Hemolytic Anemia Therapeutics Report Years Considered

    Figure 12. Global Autoimmune Hemolytic Anemia Therapeutics Market Size (US$ Million), Year-over-Year: 2018-2029

    Figure 13. Global Autoimmune Hemolytic Anemia Therapeutics Market Size, (US$ Million), 2018 VS 2022 VS 2029

    Figure 14. Global Autoimmune Hemolytic Anemia Therapeutics Market Share by Region: 2022 VS 2029

    Figure 15. Global Autoimmune Hemolytic Anemia Therapeutics Market Share by Players in 2022

    Figure 16. Global Top Autoimmune Hemolytic Anemia Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Autoimmune Hemolytic Anemia Therapeutics as of 2022)

    Figure 17. The Top 10 and 5 Players Market Share by Autoimmune Hemolytic Anemia Therapeutics Revenue in 2022

    Figure 18. North America Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 19. North America Autoimmune Hemolytic Anemia Therapeutics Market Share by Country (2018-2029)

    Figure 20. United States Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 21. Canada Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 22. Europe Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 23. Europe Autoimmune Hemolytic Anemia Therapeutics Market Share by Country (2018-2029)

    Figure 24. Germany Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 25. France Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 26. U.K. Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 27. Italy Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 28. Russia Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 29. Nordic Countries Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 30. Asia-Pacific Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 31. Asia-Pacific Autoimmune Hemolytic Anemia Therapeutics Market Share by Region (2018-2029)

    Figure 32. China Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 33. Japan Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 34. South Korea Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 35. Southeast Asia Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 36. India Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 37. Australia Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 38. Latin America Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 39. Latin America Autoimmune Hemolytic Anemia Therapeutics Market Share by Country (2018-2029)

    Figure 40. Mexico Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 41. Brazil Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 42. Middle East & Africa Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 43. Middle East & Africa Autoimmune Hemolytic Anemia Therapeutics Market Share by Country (2018-2029)

    Figure 44. Turkey Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 45. Saudi Arabia Autoimmune Hemolytic Anemia Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 46. Amneal Pharmaceuticals Inc Revenue Growth Rate in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023)

    Figure 47. Baxter International Inc Revenue Growth Rate in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023)

    Figure 48. F. Hoffmann-La Roche Ltd Revenue Growth Rate in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023)

    Figure 49. Incyte Corp Revenue Growth Rate in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023)

    Figure 50. Kezar Life Sciences Inc Revenue Growth Rate in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023)

    Figure 51. Pfizer Inc Revenue Growth Rate in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023)

    Figure 52. Rigel Pharmaceuticals Inc Revenue Growth Rate in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023)

    Figure 53. Sanofi Revenue Growth Rate in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023)

    Figure 54. Teva Pharmaceutical Industries Ltd Revenue Growth Rate in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023)

    Figure 55. Horizo​​n Revenue Growth Rate in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023)

    Figure 56. Genentech Revenue Growth Rate in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023)

    Figure 57. Zydus Cadila Revenue Growth Rate in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023)

    Figure 58. Concord Biotech Revenue Growth Rate in Autoimmune Hemolytic Anemia Therapeutics Business (2018-2023)

    Figure 59. Bottom-up and Top-down Approaches for This Report

    Figure 60. Data Triangulation

    Figure 61. Key Executives Interviewed